TY - JOUR
T1 - Korean Practice Guidelines for Gastric Cancer 2024
T2 - An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline)
AU - The Development Working Group for the Korean Practice Guideline for Gastric Cancer 2024 Task Force Team
AU - Kim, In Ho
AU - Kang, Seung Joo
AU - Choi, Wonyoung
AU - Seo, An Na
AU - Eom, Bang Wool
AU - Kang, Beodeul
AU - Kim, Bum Jun
AU - Min, Byung Hoon
AU - Tae, Chung Hyun
AU - Choi, Chang In
AU - Lee, Choong Kun
AU - An, Ho Jung
AU - Byun, Hwa Kyung
AU - Im, Hyeon Su
AU - Kim, Hyung Don
AU - Cho, Jang Ho
AU - Pak, Kyoungjune
AU - Kim, Jae Joon
AU - Bae, Jae Seok
AU - Yu, Jeong Il
AU - Lee, Jeong Won
AU - Choi, Jungyoon
AU - Kim, Jwa Hoon
AU - Choi, Miyoung
AU - Jung, Mi Ran
AU - Seo, Nieun
AU - Eom, Sang Soo
AU - Ahn, Soomin
AU - Kim, Soo Jin
AU - Lee, Sung Hak
AU - Lim, Sung Hee
AU - Kim, Tae Han
AU - Han, Hye Sook
N1 - Publisher Copyright:
© 2025. Korean Gastric Cancer Association.
PY - 2025/1
Y1 - 2025/1
N2 - Gastric cancer is one of the most common cancers in both Korea and worldwide. Since 2004, the Korean Practice Guidelines for Gastric Cancer have been regularly updated, with the 4th edition published in 2022. The 4th edition was the result of a collaborative work by an interdisciplinary team, including experts in gastric surgery, gastroenterology, endoscopy, medical oncology, abdominal radiology, pathology, nuclear medicine, radiation oncology, and guideline development methodology. The current guideline is the 5th version, an updated version of the 4th edition. In this guideline, 6 key questions (KQs) were updated or proposed after a collaborative review by the working group, and 7 statements were developed, or revised, or discussed based on a systematic review using the MEDLINE, Embase, Cochrane Library, and KoreaMed database. Over the past 2 years, there have been significant changes in systemic treatment, leading to major updates and revisions focused on this area. Additionally, minor modifications have been made in other sections, incorporating recent research findings. The level of evidence and grading of recommendations were categorized according to the Grading of Recommendations, Assessment, Development and Evaluation system. Key factors for recommendation included the level of evidence, benefit, harm, and clinical applicability. The working group reviewed and discussed the recommendations to reach a consensus. The structure of this guideline remains similar to the 2022 version. Earlier sections cover general considerations, such as screening, diagnosis, and staging of endoscopy, pathology, radiology, and nuclear medicine. In the latter sections, statements are provided for each KQ based on clinical evidence, with flowcharts supporting these statements through meta-analysis and references. This multidisciplinary, evidence-based gastric cancer guideline aims to support clinicians in providing optimal care for gastric cancer patients.
AB - Gastric cancer is one of the most common cancers in both Korea and worldwide. Since 2004, the Korean Practice Guidelines for Gastric Cancer have been regularly updated, with the 4th edition published in 2022. The 4th edition was the result of a collaborative work by an interdisciplinary team, including experts in gastric surgery, gastroenterology, endoscopy, medical oncology, abdominal radiology, pathology, nuclear medicine, radiation oncology, and guideline development methodology. The current guideline is the 5th version, an updated version of the 4th edition. In this guideline, 6 key questions (KQs) were updated or proposed after a collaborative review by the working group, and 7 statements were developed, or revised, or discussed based on a systematic review using the MEDLINE, Embase, Cochrane Library, and KoreaMed database. Over the past 2 years, there have been significant changes in systemic treatment, leading to major updates and revisions focused on this area. Additionally, minor modifications have been made in other sections, incorporating recent research findings. The level of evidence and grading of recommendations were categorized according to the Grading of Recommendations, Assessment, Development and Evaluation system. Key factors for recommendation included the level of evidence, benefit, harm, and clinical applicability. The working group reviewed and discussed the recommendations to reach a consensus. The structure of this guideline remains similar to the 2022 version. Earlier sections cover general considerations, such as screening, diagnosis, and staging of endoscopy, pathology, radiology, and nuclear medicine. In the latter sections, statements are provided for each KQ based on clinical evidence, with flowcharts supporting these statements through meta-analysis and references. This multidisciplinary, evidence-based gastric cancer guideline aims to support clinicians in providing optimal care for gastric cancer patients.
KW - Chemotherapy
KW - Endoscopy
KW - Guidelines
KW - Stomach neoplasms
KW - Surgery
UR - https://www.scopus.com/pages/publications/85215991134
U2 - 10.5230/jgc.2025.25.e11
DO - 10.5230/jgc.2025.25.e11
M3 - Article
AN - SCOPUS:85215991134
SN - 2093-582X
VL - 25
SP - 5
EP - 114
JO - Journal of Gastric Cancer
JF - Journal of Gastric Cancer
IS - 1
ER -